Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aslan Pharmaceuticals Ltd.
Headquarters: Singapore
Website: N/A
Year Founded: 2010
Status: Out of Business
BioCentury | Feb 13, 2025
Management Tracks
Lee joins Lycia as CMO
Plus: Firth joins Panacea, Lakewood appoints Manion chair and updates from Ai Proteins, Cognito and Kala
BioCentury | Aug 6, 2024
Management Tracks
A trio of hires at 4D
Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more
BioCentury | Jul 18, 2024
Management Tracks
CMO Parsey to leave Gilead
Plus: Bodmer to lead Nucleome as CEO and updates from Nouscom, Oxford Biomedica and Aslan
BioCentury | Feb 28, 2024
Deals
Asia’s ‘Arc of Innovation’: a podcast preview of BioCentury’s East-West Summit
Evolving biotech ecosystems, trends in deals and science, and highlights of the March 4-6 conference
BioCentury | Apr 25, 2023
Finance
Could Singapore become the next global biotech hub?
Local investors, global VCs aim to shape Singapore’s next biotechs
BioCentury | Feb 1, 2022
Deals
New start-up Oak Hill to advance ‘de-prioritized’ Takeda rare disease candidates
Oak Hill to house neonatology, immunology assets from Takeda-Shire deal; pharma will hold a minority stake
BioCentury | Mar 2, 2021
Regulation
Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex
Novavax Inc. (NASDAQ:NVAX) said in its 4Q20 earnings report that it is discussing COVID-19 vaccine NVX-CoV2373 with FDA and may submit a request for emergency use authorization of candidate next
BioCentury | Aug 8, 2020
Management Tracks
PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more
BioCentury | Jul 22, 2020
Finance
July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain
BioCentury | Dec 3, 2019
Financial News
Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron
Items per page:
1 - 10 of 51